Navigation Links
Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
Date:4/9/2008

SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it has reached the data cutoff date for the Company's Phase 3 registration trial of Specifid(TM) (mitumprotimut-T, formerly FavId(R)) following Rituxan(R) in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). As of the data cutoff date, 205 of the 349 patients randomized have experienced disease progression (relapsed) according to investigator determination. Final analysis will be based on a central radiology assessment of the patients' CT scans. Unblinding of the data is expected to occur in June 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

Median follow-up for ongoing patients is 31 months from randomization (range 21 to 41 months), or approximately 34 months from the initiation of Rituxan treatment (range 24 to 44 months). Based on the protocol's assumptions, this range of follow-up would provide sufficient power to detect a significant difference between the two arms for time to progression (TTP), the primary endpoint in the trial.

"We believe the design and execution of this registration trial have positioned us well for success," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "Based on the status of patients at data cutoff and our assumptions about the behavior of the control arm in this trial, we are very encouraged that the upcoming analysis will provide an outcome which is both clinically and statistically significant. Our clinical and biometrics
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
2. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
6. Medarex Announces Ipilimumab Program Continues to Move Forward
7. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
8. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
9. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
10. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008).../- CEL-SCI Corporation,(NYS... a Material Transfer,Agreement (MTA) with the Nati...and the laboratory of Dr. Francesco M. Marincola, ...s to the tumor microenvironment,caused by CEL-SCI,...f of,the Infectious Disease and Immunogentics Sect...
(Date:10/7/2008)...d Today at ACG Annual Scientific Meeting -, ORLAN...d,Pharmaceuticals, Inc. (formerly Microbia, Inc.) ...announced the presentation of results from a Phase...acy in 420 patients with,irritable bowel syndrome ...dicates that once- daily oral dosing of linaclotid...
(Date:10/7/2008)...ghlighting CIMZIA,s long-term benefits and value i...ented at American College,of Gastroenterology (ACG... Data from two studies,presented this week by UCB ...Annual Meeting demonstrate that CIMZIA(R) (certoli...Tumor Necrosis Factor alpha) - provides,sustained ...
(Date:10/7/2008)...hort Enrolled in Stage A of Trial Assessing Regime...n and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNew.... (Nasdaq: PPHM ), a clinical stage biopharmaceut...the treatment of cancer and,hepatitis C virus (HCV...,enrollment in the first stage of a Phase II trial...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4U S Research Funding Continues to Flatten as U S Health Costs Climb in August 31 Science 258 1U S Research Funding Continues to Flatten as U S Health Costs Climb in August 31 Science 258 2Cepheid to Present at Thomas Weisel Partners Healthcare Conference 282 1Cepheid to Present at Thomas Weisel Partners Healthcare Conference 282 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 1Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 278 1Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 278 2
(Date:10/7/2008)...published ACSM/AHA, guidelines, INDIANAPOLIS and...nes,for physical activity released today by the U....ere met with support from the American College of,...ciation (AHA). The,organizations, which jointly pu...r, attended today,s announcement and said the guid...
(Date:10/7/2008)ANAHEIM, Calif., Oct. 7 /PRNewswire-USNewswire/ -- CHADD, the nation,s,largest organization serving people affected by AD/HD, will hold its Annual,International Conference on AD/HD November 12-1
(Date:10/7/2008)...sive whole-leg color ultrasound, study finds, ...An older, simpler test to look for blood clots in ...is as effective as a newer, more expensive test, n...that 2-point ultrasonography of the leg -- sometim...as good at detecting DVT as the newer, whole-leg, ...
(Date:10/7/2008)... the University of California, San Diego (UCSD) in...arch of advanced lung cancer by treating patients ...ccines attempt to pump up the immune system to fig...tically engineered to also trick the cancer into t...s. , The first patients have begun enrolling in ...
Breaking Medicine News(10 mins):Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2
... and college students are now co-authors in a rese...erisation of 30 macrophages has been made possible...ue of June 9, 2006 has a report of a research team...m Hatfull at the University of Pittsburgh. The rep...
...nal of Clinical Nutrition says that the poor healt...r the overweight/obesity epidemic that has the soc...betel nut, it was found that they passed the habit... Boucher, of the University of London, and colleag...
...r that actually quietens the body’s natural pain k...t and non-habit //forming pain killers and will he...Opioid peptides are natural pain relievers with re...y react to opium – throughout the body, says Dr. V...
...tute of Allergy and Infectious Diseases (NIAID), s...r the intended //protection against infection, yet...vaccinated. Such a survival advantage was observe...eams of researchers, one led by Norman L. Letvin, ...
Other Medicine News:Health News:Transporter offers reliable clues for safer pain medicine 2Health News:Transporter offers reliable clues for safer pain medicine 3Health News:HIV Vaccine for Monkeys Increases Survival Rates 2Health News:HIV Vaccine for Monkeys Increases Survival Rates 3
...Intermec has an installed base of field-proven bar...spital departments using Intermec media include; r...y, Admissions, Nursing Stations, Pharmacy, Medical...ing materials includes many products that are fitt...
...MediCopia is a system for inpatient caregiving tha...a's automated computer system offers four technolo...are a handheld computer (for work order processing...cation), thermal printer (for label generation at ...
For superior bar code scanning performance with maximum user comfort at a highly attractive price, the LS 4000i Scanner Series from Symbol Technologies establishes an award-winning standard of excell
The IMAGETEAM 4600 SR / SF area imager from Hand Held Products combines the versatility of area imaging with the speed and cost of linear scanning for healthcare, retail and commercial applications.
Medicine Products: